Portal de Periódicos da CAPES

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

2013; Massachusetts Medical Society; Volume: 369; Issue: 11 Linguagem: Inglês

10.1056/nejmoa1305275

1533-4406

Jean‐Yves Douillard, Kelly S. Oliner, Salvatore Siena, Josep Tabernero, Ronald L. Burkes, Mario Barugel, Yves Humblet, G. Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocáková, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, Jean Luc Canon, M. Rother, Richard T. Williams, Alan Rong, Jeffrey S. Wiezorek, Roger Sidhu, Scott D. Patterson,

Gastric Cancer Management and Outcomes

Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti–epidermal growth factor receptor (EGFR) therapy. Other activating RAS mutations may also be negative predictive biomarkers for anti-EGFR therapy.